# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences comp...
Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients.Gemini could potentially revolu...
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08082025_REVB_Sorensen.pdf
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(7.01) per share which missed the analyst consensus estimate...